Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

This was the stock's third consecutive day of gains.

This comprehensive analysis examines Vertex's position in the market ... Vertex has demonstrated robust financial performance, with its stock price increasing by 109% year-to-date as of December ...

Vertex also conducted post-hoc analyses showing variability ... Benzinga Pro - Click here to start Your 14-Day Trial Now! Get ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

The analysis suggest that trial design innovation may better ... and bunionectomies (NCT05553366). "Vertex’s stock hurt after ...

This comprehensive analysis examines Vertex's current position ... You can also see if VRTX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of investment ...

Interpreting Analyst Ratings: A Closer Look The analysis of recent analyst actions ... analysts provide estimates for the future value of Vertex's stock. This comparison reveals trends in analysts ...

InvestingPro subscribers get access to exclusive analysis, including 13+ additional ProTips and comprehensive valuation metrics. Vertex has demonstrated robust financial performance, with its stock ...